Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have failed prior therapies

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the design and outcomes of the ACIS study investigating the combination of apalutamide and abiraterone plus prednisone (AAP) versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the PROSPER clinical trial investigating the role of enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) as presented at ASCO GU 2021 and considers whether PSA is an accurate marker for survival

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, offers a message for prostate cancer patients regarding the clinical developments from ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, regarding the preliminary analysis of combination belzutifan (an oral HIF-2α inhibitor) and cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers the role of precision medicine in prostate cancer and the clinical significance of the PROFOUND trial from the 2021 Genitourinary Cancers Symposium

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the prostate-specific membrane antigen (PSMA) lutetium and outcomes from the VISION clinical trial presented at ASCO GU 2021

Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, tells us about the real-world analysis of abiraterone acetate and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) as presented at the 2021 Genitourinary Cancers Symposium

Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, regarding the quality of life outcomes from the CheckMate 9ER clinical trial investigating combination nivolumab and cabozantinib in 1st-line renal cell carcinoma (RCC) as presented at ASCO GU 2021

Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, provides perspective on the CheckMate 9ER clinical trial presented at ASCO GU 2021

Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, provides a summary of the ACIS study evaluating the combination of apalutamide and abiraterone plus prednisone (AAP) versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, tells us about the design and outcomes of the EV-301 clinical study investigating enfortumab vedotin in patients with previously treated advanced urothelial cancer (UC)

Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, regarding the significance of the CLEAR trial, a three-arm study designed to compare lenvatinib plus pembrolizumab versus sunitinib and lenvatinib plus everolimus versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC)

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, regarding outcomes from Cohort 2 of the EV-201 clinical trial as presented at the 2021 Genitourinary Cancers Symposium

Dr. Oh, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, considers the role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, offers opinion on the use of nivolumab as an adjuvant treatment for muscle-invasive urothelial carcinoma as a result of CheckMate 274

Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, tells us about the treatment of clear cell renal cell carcinoma (ccRCC) with cabozantinib and belzutifan, a hypoxia-inducible factor (HIF)-2α inhibitor

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares perspective on the role of PD-L1 testing in previously untreated, locally advanced or metastatic urothelial carcinoma (mUC) as seen in the Phase III IMvigor130 study presented at ASCO GU 2021

Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, shares thoughts on the TIVO-3 trial investigating tivozanib in the treatment of renal cell carcinoma (RCC) as presented at the 2021 Genitourinary Cancers Symposium

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares a message for patients regarding clinical progress in bladder cancer as seen at the 2021 Genitourinary Cancers Symposium